Hikma Pharmaceuticals (HIK) Competitors GBX 1,862 +17.00 (+0.92%) (As of 08:35 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability HIK vs. HCM, INDV, AMYT, AGY, APH, BXP, ANCR, DNL, EAH, and STXShould you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Diurnal Group (DNL), ECO Animal Health Group (EAH), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry. Hikma Pharmaceuticals vs. HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Beximco Pharmaceuticals Animalcare Group Diurnal Group ECO Animal Health Group Shield Therapeutics HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Is HCM or HIK more profitable? Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.88% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMED-6.87% -5.44% -5.90% Hikma Pharmaceuticals 9.45%12.88%9.40% Which has more risk & volatility, HCM or HIK? HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Do insiders and institutionals hold more shares of HCM or HIK? 36.5% of HUTCHMED shares are owned by institutional investors. Comparatively, 42.1% of Hikma Pharmaceuticals shares are owned by institutional investors. 39.0% of HUTCHMED shares are owned by company insiders. Comparatively, 30.5% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate HCM or HIK? Hikma Pharmaceuticals has a consensus price target of GBX 2,383.33, suggesting a potential upside of 29.18%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Hikma Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable valuation & earnings, HCM or HIK? Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED£610.81M3.97-£41.97M-£0.04-7,100.00Hikma Pharmaceuticals£3.02B1.36£285M£0.652,838.46 Does the MarketBeat Community favor HCM or HIK? Hikma Pharmaceuticals received 604 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.55% of users gave Hikma Pharmaceuticals an outperform vote. CompanyUnderperformOutperformHUTCHMEDOutperform Votes19678.40% Underperform Votes5421.60% Hikma PharmaceuticalsOutperform Votes80070.55% Underperform Votes33429.45% Does the media refer more to HCM or HIK? In the previous week, HUTCHMED had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Hikma Pharmaceuticals. HUTCHMED's average media sentiment score of 1.11 beat Hikma Pharmaceuticals' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media. Company Overall Sentiment HUTCHMED Positive Hikma Pharmaceuticals Neutral SummaryHikma Pharmaceuticals beats HUTCHMED on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIK vs. The Competition Export to ExcelMetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£4.09B£1.17B£5.06B£1.48BDividend Yield3.25%3.13%5.18%11.75%P/E Ratio2,838.46110.02126.311,622.87Price / Sales1.362,121.991,178.74232,521.30Price / Cash8.3410.4333.8631.75Price / Book1.793.134.682.68Net Income£285M£159.31M£119.54M£161.21M7 Day Performance2.84%-1.09%-1.83%-0.60%1 Month Performance-7.61%-3.75%-3.60%7.85%1 Year Performance4.96%87.93%31.91%19.06% Hikma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIKHikma Pharmaceuticals2.7793 of 5 starsGBX 1,862+0.9%GBX 2,383.33+28.0%+5.3%£4.13B£3.02B2,864.629,100HCMHUTCHMEDN/AGBX 280-1.4%N/A-4.7%£2.39B£610.81M-7,100.001,760Positive NewsINDVIndivior2.1311 of 5 starsGBX 825.50-0.1%GBX 1,500+81.7%-38.8%£1.06B£1.15B-1,033.131,000AMYTAmryt PharmaN/AGBX 143-11.7%N/A+0.0%£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 5.10-7.3%N/A+205.6%£243.27M£53.26M-91.67612Gap DownAPHAlliance Pharma2.5903 of 5 starsGBX 44.88+1.3%GBX 60+33.7%+16.6%£242.59M£183.15M-745.8391,000BXPBeximco PharmaceuticalsN/AGBX 34+4.6%N/A-24.4%£151.68M£43.08B425.005,500Gap UpANCRAnimalcare GroupN/AGBX 247.90-0.4%N/A+41.6%£149.66M£76.10M3,086.25220News CoverageDNLDiurnal GroupN/AGBX 27.30flatN/A+0.0%£46.33M£4.68M-3.2133EAHECO Animal Health GroupN/AGBX 65.45-0.8%N/A-41.3%£44.34M£89.42M3,300.00234Gap DownSTXShield TherapeuticsN/AGBX 2.91+8.9%N/A-56.1%£22.78M£21.47M-79.4340,000News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Beximco Pharmaceuticals Alternatives Animalcare Group Alternatives Diurnal Group Alternatives ECO Animal Health Group Alternatives Shield Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HIK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
